澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CSL LIMITED

114.990

+2.9502.63%

成交量：182.63萬

成交額：2.11億

市值：550.70億

市盈率：27.70

高：117.110

開：114.470

低：112.670

收：112.040

52周最高：269.118

52周最低：90.000

股本：4.79億

流通股本：4.79億

量比：0.55

換手率：0.38%

股息：4.24

股息率：3.69%

每股收益(TTM):4.151

每股收益(LYR):8.962

淨資產收益率：6.66%

總資產收益率：6.58%

市淨率：2.03

市盈率(LYR):12.83

資料載入中...

總覽公司新聞公告

FDA顧問委員會支持莫德納mRNA流感疫苗

數據簡報-全球製藥企業斥資數十億美元以擴大在美國的市場份額

異動解讀 | 英國批准AUJEMFLU流感疫苗，CSL LIMITED盤中大漲5.02%

英國MHRA批准AUJEMFLU用於50歲及以上成人流感防護

熱門話題-儘管表現欠佳，晨星仍維持對CSL的公允價值評級

澳大利亞TGA：苯青黴素注射劑產品將逐步停產，600毫克規格自11月30日起首當其衝，原因系商業考量

澳大利亞TGA：未來或將有更多本土註冊的青黴素鈉注射劑品牌上市

澳大利亞TGA：特定苄星青黴素鈉注射液產品將持續供應至庫存耗盡

CSL加拿大宣佈首例加拿大患者於安大略省接受Hemgenix®血友病B基因療法

泛美衞生組織簽署協議為拉美及加勒比地區預留大流行流感疫苗供應

異動解讀 | 花旗下調評級與目標價，CSL盤中大跌5.74%

熱門話題-花旗下調目標價，晨星敦促公司聘請新首席執行官，CSL股價下跌6%

異動解讀 | CSL預計美國免疫球蛋白渠道庫存正常化影響收入，股價盤中大跌10.49%

CSL有限公司下調財年展望並計提50億澳元減值，早盤股價重挫10.8%

CSL預計美國免疫球蛋白渠道庫存正常化將影響2026財年3億美元收入

澳大利亞 CSL 受五角大樓流感政策轉變影響，股價跌至 2017 年新低

BUZZ-花旗銀行認為季度增長強勁，但可能對瑞思邁的成本產生影響

美國行政公告確認血漿衍生療法的獨特性，CSL有限公司受益

CSL 表示出血性疾病基因療法全球缺貨

CSL有限公司正與監管機構協作制定策略確保Hemgenix持續穩定供應

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CSL.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":114.99,"timestamp":1782281520000,"preClose":112.04,"halted":0,"volume":1826320,"delay":0,"changeRate":0.02632988218493385,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":4.1513178249533365,"marketStatus":"已收盤","change":2.95,"latestTime":"06-24 16:12:00 AEST","open":114.47,"high":117.11,"low":112.67,"amount":210654876,"amplitude":0.039629,"askPrice":115,"askSize":799,"bidPrice":114.95,"bidSize":87,"shortable":3,"etf":0,"ttmEps":4.1513178249533365,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1782345600000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":112.04,"dividendRate":0.036708,"openAndCloseTimeList":[[1782259200000,1782280800000]],"volumeRatio":0.545185,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":112.04,"auctionPrice":114.99,"auctionVolume":421126,"auctionTime":1782281409339,"referencePrice":114.99,"referenceTime":1782297003090,"auction":3,"marketStatus":"盘后竞价","timestamp":1782281409339}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"6.58%","roe":"6.66%","lyrEps":8.962225,"volumeRatio":0.545185,"shares":478911979,"dividePrice":4.241443,"high":117.11,"amplitude":0.039629,"preClose":112.04,"low":112.67,"week52Low":90,"pbRate":"2.03","psRate":"2.46","week52High":269.118,"institutionHeld":0,"latestPrice":114.99,"committee":-0.803612,"eps":4.1513178249533365,"divideRate":0.036885,"volume":1826320,"delay":0,"ttmEps":4.1513178249533365,"open":114.47,"prevYearClose":170.408,"prevWeekClose":116.32,"prevMonthClose":96.61,"prevQuarterClose":140.78,"fiveDayClose":106.79,"twentyDayClose":96.9,"sixtyDayClose":143.19,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":4,"dividendGrowthRate":0.11620984529927163,"fiveYearAvgDividendRate":0.013228653048611719},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"},{"date":"2025-08-19","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755561600000,"name":null,"time":"","dateTimestamp":1755525600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2644044607","title":"FDA顧問委員會支持莫德納mRNA流感疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2644044607","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644044607?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 18:00","pubTimestamp":1781776840,"startTime":"0","endTime":"0","summary":"更新版 3-FDA顾问委员会支持莫德纳mRNA流感疫苗在第4段中补充了股价走势，在第7段中补充了专家评论，在第10、12段中补充了分析师评论FDA顾问委员会认可mFlusiva对50岁及以上成年人的疗效该机构最初曾驳回莫德纳公司的申请预计FDA将于8月5日前作出批准决定这将成为美国首款季节性流感mRNA疫苗Christy Santhosh/Mariam Sunny","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nL4T42Q0TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4585","IE00BKPKM643.USD","LU1084165304.USD","LU0310799852.SGD","MRNY","LU0289739699.SGD","SG9999001176.USD","LU0058720904.USD","LU0128525689.USD","MRNX","LU1057294990.SGD","LU0920840948.USD","CSL.AU","LU0553294199.USD","03165","LU0889565080.SGD","LU1983299246.USD","MRNA","LU1196032939.SGD","SG9999013999.USD","LU0158827948.USD","LU1496350171.SGD","LU0960981461.USD","LU0784385840.USD","LU1267930573.SGD","LU1496350502.SGD","LU0661504455.SGD","LU1078025761.USD","SG9999001176.SGD","LU2293690082.USD","LU0784385170.HKD","LU0171293334.USD","LU0889566641.SGD","LU0077335932.USD","LU1019634622.SGD","LU1153585028.USD","LU0784384876.USD","IE00B4R5TH58.HKD","LU0128525929.USD","LU0203347892.USD","AZN.UK","LU0029864427.USD","LU0211326839.USD","IE00BJT1NW94.SGD","LU1487256676.USD","LU2237443895.HKD","BK4551","LU0784383803.USD","LU1880407215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643520595","title":"數據簡報-全球製藥企業斥資數十億美元以擴大在美國的市場份額","url":"https://stock-news.laohu8.com/highlight/detail?id=2643520595","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643520595?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 20:41","pubTimestamp":1781527269,"startTime":"0","endTime":"0","summary":"路透6月15日 - 全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔市投资约10亿美元，以加强其眼科护理业务在美国本土的制造能力。默克动物保健部门将投资8.95亿美元，用于扩建其位于堪萨斯州的制造和研发基地，这是该公司截至2028年总额达90亿美元的美国投资计划的一部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nL4T42N15M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2756315664.SGD","SG9999001440.SGD","IE00B42XCP33.USD","LU0738911758.USD","LU1934455277.USD","LU2361044865.SGD","LU2750360641.GBP","AZN","LU2125154778.USD","LU0211327993.USD","BK4534","AZNH","LU1064131342.USD","LU2112291526.USD","LU2237443895.HKD","LU0354030438.USD","LU1917777945.USD","IE00B7SZLL34.SGD","LU0345769631.USD","LU1674673428.USD","IE00B4R5TH58.HKD","LU1699723380.USD","IE00B3PB1722.GBP","LU1267930813.SGD","IE00BDGV0183.EUR","LU1280957306.USD","IE000WAW04H5.SGD","SGXZ81514606.USD","IE0004445015.USD","LU0965509283.SGD","LU2237443465.HKD","LU2471134952.CNY","LU2491050154.USD","PFE","LU1496350171.SGD","LLYX","LU1093756325.SGD","LU1032466523.USD","IE00B1BXHZ80.USD","LU2360106947.USD","LU1066051225.USD","LU0225284248.USD","SG9999015945.SGD","LU1989771016.USD","SG9999015358.SGD","LU2264538146.SGD","LU2417539215.USD","LU0353189763.USD","LU0943347566.SGD","LU1221951046.USD","LU1267930490.SGD","LU1934455194.USD","SG9999002224.SGD","IE000M9KFDE8.USD","LU1244550221.USD","LU0823434583.USD","LU1923622614.USD","LU2133065610.SGD","LU2602419157.SGD","LU0949170772.SGD","LU0225283273.USD","LU0965509010.AUD","LU2324357040.USD","BK4581","IE00BJJMRY28.SGD","LU1670628061.USD","BK4559","SG9999014906.USD","LU1670627923.USD","LU0114720955.EUR","LU2271345857.HKD","LU2236285917.USD","SG9999002232.USD","SG9999018857.SGD","LU0306806265.USD","LU0170899867.USD","LU1894683348.USD","SG9999015978.USD","IE00B19Z9P08.USD","BK4139","IE00BZ1G4Q59.USD","BK4566","SG9999015986.USD","LU0472753341.HKD","LU0985481810.HKD","LU0109394709.USD","LU2063271972.USD","LU0661504455.SGD","LU2125909247.SGD","LU0859254822.USD","LU1989772923.USD","LU1989772840.SGD","LU0545039389.USD","LU2237443382.USD","LU1035773651.USD","LU0094547139.USD","LU2491050071.SGD","LU1496350502.SGD","LU0889565916.HKD","LU1116320901.HKD","LLY","LU0912757837.SGD","LU1868837136.USD","LU0128525929.USD","SGXZ99366536.SGD","BK4504","IE000F7OJYX1.SGD","LU0820561818.USD","IE0034235303.USD","LU2168564065.EUR","BK4533","IE00BWXC8680.SGD","LU0210536198.USD","LU1037948541.HKD","BK4568","LU2403377893.USD","LU0203201768.USD","LU0477156953.USD","LU1059921491.USD","SGXZ51526630.SGD","SG9999014559.SGD","LU1988902786.USD","LU0942090050.USD","LU0106261372.USD","LU0321505868.SGD","LU0345770308.USD","LU0320765992.SGD","LU0708994859.HKD","SG9999017495.SGD","LU0130517989.USD","IE00B4JS1V06.HKD","LU2552382058.USD","LU2505996681.GBP","SG9999014880.SGD","LU1935042991.SGD","LU2023250843.SGD","LU1778281490.HKD","IE00B1XK9C88.USD","IE00BK4W5M84.HKD","LU1074936037.SGD","LU1804176565.USD","LU1127390331.HKD","LU0058720904.USD","LU2168564495.EUR","GILD","LU0266013472.USD","LU2462157665.USD","IE00BJJMRX11.SGD","IE00BFXG1179.USD","SG9999014567.USD","LU1929549753.HKD","LU1883839398.USD","LU2237443622.USD","LU1043141396.HKD","LU1674673691.USD","ELIL","IE00BN29S564.USD","LU0466842654.USD","LU1868837300.USD","LU1548497426.USD","LU0354030511.USD","LU2237438978.USD","LU2360032135.SGD","LU2430703251.USD","LU2433249047.HKD","LU1941712264.USD","LU0130102774.USD","LU0708995401.HKD","LU0321505439.SGD","LU1366192091.USD","LU0070302665.USD","SG9999018865.SGD","CSL.AU","MRK","LU0109391861.USD","LU1066051498.USD","BK7511","LU0238689110.USD","LU1003077747.HKD","LU1814569148.SGD","SG9999011175.SGD","LU0158827948.USD","LU0256863811.USD","SG9999014914.USD","LU1023059063.AUD","LU2023250330.USD","IE0004445239.USD","LU0006306889.USD","LU0545562505.USD","LU2111349929.HKD","LU0823416689.USD","LU1267930573.SGD","BK4578","LU0122379950.USD","LU0861579265.USD","IE00B19Z9Z06.USD","LU1712237335.SGD","LU0323591593.USD","LU1506573853.SGD","BK7508","LU1201861249.SGD","LU1585245621.USD","LU0097036916.USD","LU0320765646.SGD","LU2265009873.SGD","IE00B19Z3B42.SGD","LU0079474960.USD","LU0211328371.USD","LU2242646821.SGD","LU0689472784.USD","LU0124676726.USD","LU1551013425.SGD","LU0289739343.SGD","LU2087621335.USD","LU2471134796.USD","LU2361045086.USD","LU0689626769.HKD","LU2125909593.SGD","LU0070217475.USD","LU0471298694.HKD","LU0345770993.USD","LU1196500208.SGD","LU0795875086.SGD","IE0002141913.USD","LU0787776722.HKD","BK4588","LU0432979614.USD","GSKH","LU2168564222.USD","LU0882574139.USD","LU1868836591.USD","LU1829250122.USD","LU2750360997.AUD","LU2430703095.HKD","IE00BLSP4452.SGD","LU1571399168.USD","LU2461242641.AUD","LU1043141123.HKD","IE0001KFT4U8.USD","IE00B2B36J28.USD","SG9999015341.SGD","LU0203347892.USD","LU0306807586.USD","LU0385154629.USD","LU0820561909.HKD","BIIB","LU2168563687.JPY","LU0456855351.SGD","LU2213496289.HKD","LU2430703178.SGD","LU2471134523.USD","LU1291159041.SGD","LU1267930730.SGD","LU2023251221.USD","LU0057025933.USD","LU2237443978.SGD","LU1228905540.USD","LU1232071149.USD","IE000SO60NU8.SGD","LU0965508806.USD","LU1116320737.USD","SG9999003800.SGD","SG9999001176.USD","LU0029864427.USD","LU2028103732.USD","SG9999014542.SGD","04332","LU1941712348.USD","IE00BK4W5L77.USD","LU0225771236.USD","LU0889566641.SGD","LU0098860793.USD","LU0426417589.USD","LU0289739699.SGD","LU1032955483.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","SG9999015952.SGD","SG9999014898.SGD","LU1720051108.HKD","LU1069347547.HKD","BK4592","LU2456880835.USD","BK4550","LU0426412945.USD","LU1983299246.USD","LU0980610538.SGD","LU0133085943.USD","LU2089283258.USD","LU2089284900.SGD","LU1629891620.HKD","IE00BVYPNW00.USD","SG9999013999.USD","LU1066053197.SGD","LU1718418525.SGD","LU2347655156.SGD","LU0096364046.USD","GB00BDT5M118.USD","LU2491049909.HKD","BK4599","LU2592432038.USD","IE00BFTCPJ56.SGD","IE0005OL40V9.USD","LLII","LU2357627491.SGD","BK7067","LU1228905037.USD","LU0210528500.USD","LU2746668461.USD","LU1261432733.SGD","IE00BN8TJ469.HKD","LU1057294990.SGD","BK4516","LU2596442595.SGD","JNJ","LU0964807845.USD","LU0985320562.USD","LU2129689514.USD","IE00BJT1NW94.SGD","LU2023250504.SGD","LU1974910355.USD","AMGN","LU0882574055.USD","LU2168564149.EUR","LU2087625088.SGD","LU0820562030.AUD","LU0553294199.USD","IE00BKVL7J92.USD","LU0417517546.SGD","IE0009355771.USD","LU0648001328.SGD","IE00BBT3K403.USD","IE0000B7K699.USD","LU1121112475.USD","IE00BLSP4239.USD","LU2756315318.SGD","ABBV","IE00BVYPNV92.GBP","LU2471134879.HKD","BK4583","LU0061475181.USD","LU0320765059.SGD","LU2237443549.SGD","LU0786609619.USD","LU1732799900.SGD","LU2896262040.SGD","LU0868494708.USD","LU1934455863.HKD","LU1069344957.HKD","LU0640476718.USD","LU2357305700.SGD","LU0310799852.SGD","LU0511384066.AUD","GSK.UK","LU0158827781.USD","LU0211331839.USD","LU0265550359.USD","LU2211815571.USD","LU0792757196.USD","LU1061106388.HKD","BK4532","LU0069063385.USD","IE000MB6IJN5.SGD","LU2746668974.SGD","LU0198837287.USD","LU1035775433.USD","LU0310800379.SGD","IE0002270589.USD","BK4007","IE00B19Z3581.USD","LU0208291251.USD","LU1323610961.USD","IE00B775H168.HKD","LU1145028129.USD","GSK","IE00BJLML261.HKD","LLYZ","LU2129689605.HKD","LU0234570918.USD","IE000BZT7R73.USD","LU0823434740.USD","LU0868494617.USD","IE00B894F039.SGD","LU1430594728.SGD","LU1894683264.USD","LU1720051017.SGD","BK7501","LU1732800096.USD","LU2108987350.USD","LU1623119135.USD","LU1066051811.HKD","IE00BFSS8Q28.SGD","SGXZ31699556.SGD","LU0965509101.SGD","LU2487616109.SGD","LU2505996509.AUD","LU0234572021.USD","LU0683600562.USD","LU1551013342.USD","LU1162221912.USD","SG9999014575.USD","LU0289961442.SGD","LU2125154935.USD","LU0795875169.SGD","LU1868836757.USD","LU0994945656.USD","LU1914381329.SGD","LU2089984988.USD","LU0353189680.USD","LU0316494557.USD","LU2106854487.HKD","LU0672654240.SGD","LU1868836914.USD","LU2129689431.USD","IE00B7KXQ091.USD","LU1839511570.USD","LU0203345920.USD","LU1037948897.HKD","LU1244550494.USD","LU0053666078.USD","IE00B3T34201.USD","LU0345769128.USD","LU0471298777.SGD","LU1093756168.USD","IE00BKDWB100.SGD","IE00BFSS7M15.SGD","IE00BKPKM429.USD","LU2242652126.USD","LU2552382215.SGD","LU2361044949.HKD","SGXZ57979304.SGD","LU1221951129.SGD","LU2552382132.HKD","LU0203202063.USD","ELIS","SG9999001176.SGD","BK4585","LU0265550946.USD","IE00BGHQF631.EUR","LU2468319806.SGD","LU0256863902.USD","IE00BSNM7G36.USD","LU1244550577.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109452273","title":"異動解讀 | 英國批准AUJEMFLU流感疫苗，CSL LIMITED盤中大漲5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109452273","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109452273?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 11:36","pubTimestamp":1780630616,"startTime":"0","endTime":"0","summary":"CSL LIMITED(CSL.AU)今日盘中大涨5.02%，引起了市场的广泛关注。消息面上，英国药品和健康产品管理局（MHRA）已批准佐剂三价流感疫苗AUJEMFLU的上市许可，该疫苗旨在为50岁及以上的成年人群提供针对流感的保护。此次批准为相关公司带来了进一步的市场覆盖机会，增强了市场对其业务增长潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104796496","title":"英國MHRA批准AUJEMFLU用於50歲及以上成人流感防護","url":"https://stock-news.laohu8.com/highlight/detail?id=1104796496","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104796496?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 00:28","pubTimestamp":1780590511,"startTime":"0","endTime":"0","summary":"英国药品和健康产品管理局（MHRA）已批准佐剂三价流感疫苗AUJEMFLU的上市许可，该疫苗旨在为50岁及以上的成年人群提供针对流感的保护。\n此次批准为相关公司带来了进一步的市场覆盖机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","CSL.AU","BK7067","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640926067","title":"熱門話題-儘管表現欠佳，晨星仍維持對CSL的公允價值評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2640926067","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640926067?lang=zh_tw&edition=fundamental","pubTime":"2026-06-03 05:33","pubTimestamp":1780436025,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL4T42A1S7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK4112","CSL.AU","LU1878469433.USD","BK4598","MORN","BK7067","LU2065731478.USD","BK7501","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163020107","title":"澳大利亞TGA：苯青黴素注射劑產品將逐步停產，600毫克規格自11月30日起首當其衝，原因系商業考量","url":"https://stock-news.laohu8.com/highlight/detail?id=1163020107","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163020107?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 15:05","pubTimestamp":1779865555,"startTime":"0","endTime":"0","summary":"澳大利亚治疗用品管理局（TGA）发布通告，苯青霉素注射剂产品将基于商业原因逐步退出市场。停产计划将自11月30日起开始实施，首当其冲的将是600毫克规格的产品。此举意味着该规格的供应将逐步减少并最终停止。后续其他规格产品的停产安排，预计将根据商业评估结果进一步公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187424614","title":"澳大利亞TGA：未來或將有更多本土註冊的青黴素鈉注射劑品牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1187424614","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187424614?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 15:05","pubTimestamp":1779865545,"startTime":"0","endTime":"0","summary":"澳大利亚治疗商品管理局（TGA）表示，未来市场上有望出现更多在澳大利亚注册的替代性青霉素钠注射剂品牌。这一预期旨在增加关键抗生素的供应来源，提升医疗系统的药品可及性与选择多样性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7511","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129937392","title":"澳大利亞TGA：特定苄星青黴素鈉注射液產品將持續供應至庫存耗盡","url":"https://stock-news.laohu8.com/highlight/detail?id=1129937392","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129937392?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 15:05","pubTimestamp":1779865544,"startTime":"0","endTime":"0","summary":"澳大利亚药品管理局（TGA）发布通告，明确特定批次的苄星青霉素钠注射液产品将继续供应，直至现有库存完全耗尽。这一决定旨在确保医疗服务的连续性，为依赖该药品的患者提供明确的供应预期。TGA将持续监控库存与分发情况，以保障公共卫生需求得到满足。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CSL.AU","BK7501","BK7067","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108861620","title":"CSL加拿大宣佈首例加拿大患者於安大略省接受Hemgenix®血友病B基因療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1108861620","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108861620?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 18:01","pubTimestamp":1779271295,"startTime":"0","endTime":"0","summary":"CSL加拿大公司宣布，首例加拿大患者已在安大略省成功接受了Hemgenix®（Etranacogene Dezaparvovec）基因疗法，用于治疗血友病B。这一里程碑事件标志着该创新疗法在加拿大临床应用的正式开启。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7501","BK7511","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169753180","title":"泛美衞生組織簽署協議 為拉美及加勒比地區預留大流行流感疫苗供應","url":"https://stock-news.laohu8.com/highlight/detail?id=1169753180","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169753180?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 02:31","pubTimestamp":1778610671,"startTime":"0","endTime":"0","summary":"泛美卫生组织（PAHO）已签署一项关键协议，旨在为拉丁美洲及加勒比地区预先保留大流行性流感疫苗的供应。此举旨在加强该区域应对未来潜在流感大流行的准备能力，确保疫苗的及时获取与分配。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7511","BK7508","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152457110","title":"異動解讀 | 花旗下調評級與目標價，CSL盤中大跌5.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152457110","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152457110?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 08:38","pubTimestamp":1778546311,"startTime":"0","endTime":"0","summary":"CSL LIMITED（CSL.AU）今日盘中大跌5.74%，引发了市场关注。消息面上，花旗集团将CSL的评级从“买入”下调至“中性”，并将其目标价从200澳元大幅下调至110澳元，同时下调了对该公司2026财年的利润预期。此外，投资研究机构晨星也下调了对CSL未来十年的营收和净利润预测。更为直接的是，CSL公司自身在近期下调了年度利润预期，并警告将计提高达50亿澳元的减值准备。晨星分析师指出，鉴于销售势头不足，公司的高营收增长前景难以令人信服，并敦促公司聘请新任首席执行官并提出清晰的发展愿景以重振旗鼓。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634514642","title":"熱門話題-花旗下調目標價，晨星敦促公司聘請新首席執行官，CSL股價下跌6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634514642","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634514642?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 08:34","pubTimestamp":1778546096,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL4T41P021:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0648001328.SGD","BK7067","LU1668664300.SGD","BK7508","LU0310800965.SGD","BK4207","LU1201861249.SGD","LU0203345920.USD","LU2125154778.USD","BK7501","LU0130517989.USD","BK4534","LU1244550494.USD","LU0314106906.USD","LU2456880835.USD","LU0128525689.USD","LU0320765646.SGD","BK4588","LU0980610538.SGD","LU2360032135.SGD","BK4559","LU1267930227.SGD","LU0052756011.USD","LU0130102774.USD","LU2236285917.USD","BK4504","LU1366192091.USD","LU1162221912.USD","LU0162691827.USD","LU0072461881.USD","LU2417539215.USD","LU0170899867.USD","LU1506573853.SGD","CSL.AU","BK4585","LU2125154935.USD","LU0477156953.USD","LU0203347892.USD","BK4566","IE00BSNM7G36.USD","LU0098860793.USD","LU1244550221.USD","LU1244550577.SGD","LU1791807156.HKD","BK7511","LU2462157665.USD","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195739661","title":"異動解讀 | CSL預計美國免疫球蛋白渠道庫存正常化影響收入，股價盤中大跌10.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195739661","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195739661?lang=zh_tw&edition=fundamental","pubTime":"2026-05-11 08:04","pubTimestamp":1778457845,"startTime":"0","endTime":"0","summary":"CSL LIMITED今日盘中大跌10.49%，引发了市场关注。消息面上，CSL LIMITED预计，美国市场免疫球蛋白产品的渠道库存恢复正常水平，将对其2026财年的收入造成约3亿美元的影响。这一负面财务预测是导致股价下跌的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168012814","title":"CSL有限公司下調財年展望並計提50億澳元減值，早盤股價重挫10.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168012814","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168012814?lang=zh_tw&edition=fundamental","pubTime":"2026-05-11 08:02","pubTimestamp":1778457757,"startTime":"0","endTime":"0","summary":"CSL有限公司在早盘交易中股价大幅下挫10.8%，此前该公司宣布下调2026财年的业绩展望，并确认了高达50亿澳元的资产减值损失。减值主要涉及部分研发项目及生产设施的账面价值调整。管理层同时调整了对2026财年的业绩指引，将原先预期的营收增长区间从“高个位数百分比”下调至“中个位数百分比”，并将核心利润增长预期从“双位数百分比”调整为“高单位数百分比”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CSL.AU","BK7501","BK7067","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108549225","title":"CSL預計美國免疫球蛋白渠道庫存正常化將影響2026財年3億美元收入","url":"https://stock-news.laohu8.com/highlight/detail?id=1108549225","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108549225?lang=zh_tw&edition=fundamental","pubTime":"2026-05-11 06:16","pubTimestamp":1778451388,"startTime":"0","endTime":"0","summary":"CSL LIMITED预计，美国市场免疫球蛋白产品的渠道库存恢复正常水平，将对其2026财年的收入造成约3亿美元的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7067","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629107268","title":"澳大利亞 CSL 受五角大樓流感政策轉變影響，股價跌至 2017 年新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2629107268","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629107268?lang=zh_tw&edition=fundamental","pubTime":"2026-04-23 08:38","pubTimestamp":1776904708,"startTime":"0","endTime":"0","summary":"澳大利亚 CSL 受五角大楼流感政策转变影响，股价跌至 2017 年新低CSL 创 2017 年 8 月底以来最低水平2026 年迄今股价下跌超过 25分析师：五角大楼此举在最糟糕的时候增加了压力Rajasik Mukherjee. CSL Seqirus 在 2025 财年的收入约为 21.7 亿美元，约占公司总收入的 14%。CSL 曾经是澳大利亚最昂贵的股票，去年却暴跌了约 39%，创下了自 2002 年以来的最大年度跌幅。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL4T41601X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7501","BK7067","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626924841","title":"BUZZ-花旗銀行認為季度增長強勁，但可能對瑞思邁的成本產生影響","url":"https://stock-news.laohu8.com/highlight/detail?id=2626924841","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626924841?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 03:30","pubTimestamp":1775676628,"startTime":"0","endTime":"0","summary":"BUZZ-花旗银行认为季度增长强劲，但可能对瑞思迈的成本产生影响4月8日 - ** 花旗预计瑞思迈RMD.AXRMD.N26财年第三季度营收为14.4亿美元，而25财年第三季度为13亿美元。** 花旗将 RMD 第三季度毛利率预期下调 10 个基点，理由是当前地缘政治局势导致成本上升。** 花旗表示：\"我们预测 RMD 的核心每股收益为 2.85 美元，接近 VA 的共识。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL4S40R1PB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4082","BK7511","BK4548","BK4504","CSL.AU","BK4567","BK4588","LU2008162690.USD","BK7501","LU0170899867.USD","BK7067","RMD","LU2177674079.SGD","IE00B5TLWC47.USD","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128146914","title":"美國行政公告確認血漿衍生療法的獨特性，CSL有限公司受益","url":"https://stock-news.laohu8.com/highlight/detail?id=1128146914","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128146914?lang=zh_tw&edition=fundamental","pubTime":"2026-04-07 06:28","pubTimestamp":1775514498,"startTime":"0","endTime":"0","summary":"美国政府在最新行政公告中明确认可了血浆衍生疗法的独特属性，这一决定对专注于该领域的CSL有限公司具有积极意义。血浆衍生疗法因其不可替代的治疗价值与复杂的生产工艺，在全球医疗体系中占据特殊地位。\n此次官方认可不仅凸显了此类疗法对患者生命健康的关键作用，更为CSL有限公司等深耕血浆技术研发的企业提供了政策支持。随着美国对血浆衍生疗法独特性的正式承认，相关企业在供应链保障和市场准入方面有望获得更有利的发展环境。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7508","BK7067","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620471351","title":"CSL 表示出血性疾病基因療法全球缺貨","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471351","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471351?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 00:37","pubTimestamp":1773765430,"startTime":"0","endTime":"0","summary":"路透3月17日 - 澳大利亚CSLCSL.AX公司表示，其出血性疾病基因疗法Hemgenix面临暂时性全球缺货，这将推迟该药物在已上市国家的部分患者的治疗。医生们认为，高昂的价格、物流问题和潜在的治疗进展前景阻碍了血友病基因疗法的采用。CSL表示，推迟治疗可能会影响到一些符合条件的患者，这些患者原本计划在已上市的国家接受一次性治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4T4051K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4533","BK4550","CSL.AU","BK7067","LU0306806265.USD","LU0985481810.HKD","SG9999013999.USD","BK7511","LU1066051498.USD","LU1066053197.SGD","SG9999001176.SGD","SGXZ57979304.SGD","SG9999002224.SGD","LU0456855351.SGD","BK4007","BK4588","BK4592","LU0234572021.USD","LU0321505868.SGD","IE000M9KFDE8.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","BK4534","LU0289739699.SGD","LU0868494617.USD","IE00B19Z3B42.SGD","LU0306807586.USD","LU1883839398.USD","SG9999001176.USD","LU0225284248.USD","SG9999002232.USD","SG9999003800.SGD","IE00BLSP4239.USD","SG9999011175.SGD","LU1023059063.AUD","LU0170899867.USD","IE0002270589.USD","LU0058720904.USD","BK7501","BK4581","IE00BLSP4452.SGD","LU1057294990.SGD","LU1894683264.USD","LU0122379950.USD","LU1894683348.USD","BK4585","LU0225771236.USD","BK7508","LU0321505439.SGD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128210509","title":"CSL有限公司正與監管機構協作制定策略 確保Hemgenix持續穩定供應","url":"https://stock-news.laohu8.com/highlight/detail?id=1128210509","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128210509?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 23:47","pubTimestamp":1773762439,"startTime":"0","endTime":"0","summary":"全球生物技术巨头CSL有限公司近日宣布，公司已启动与相关药品监管部门的密切沟通，共同探讨保障基因疗法Hemgenix长期稳定供应的战略方案。这一举措旨在应对潜在供应链挑战，确保这款突破性血友病B治疗药物能够持续满足全球患者的临床需求。通过建立多方协作机制，CSL将优化从原料采购到成品配送的全链条管理。此次战略合作凸显了CSL对患者用药可及性的长期承诺。CSL将通过技术创新与监管协作的双重路径，持续推动罕见病治疗领域的进步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7508","BK7067","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}